According to the Zhitong Finance App, Gaoshi Healthcare (02407) announced its 2026 interim results, with revenue of 595 million yuan, a year-on-year decrease of 8.9%. The company's shareholders should account for profit of 17.272 million yuan, a year-on-year decrease of 54.52%; profit per share was 0.12 yuan.

The announcement stated that due to the combination of multiple adverse factors, such as changes in market demand structure under the guidance of national policies and the termination of overseas femtosecond laser-assisted cataract surgery product agency cooperation, the Group's sales revenue for products distributed declined. However, under pressure, the Group's own product revenue grew by 4.6%, in line with the Group's development strategy. In the second half of 2026, it is expected that a number of self-developed products will be mass-produced and launched, driving continued revenue growth and helping improve the Group's overall performance.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.